Uta Griesenbach, Eric W.F.W. Alton, Department of Gene Therapy, Faculty of Medicine ... proof-of-principle for gene transfer into the cystic fibrosis (CF) lung. It is currently unknown whether ...

New breakthroughs in gene editing mean that cures for genetic diseases such as cystic fibrosis could be developed in the near ...

Fair Therapeutics B.V. has completed enrollment of its Phase IIb CHOICES trial, evaluating the novel CFTR triple modulator therapy, Diponecaftor, for adults with ultra-rare cystic fibrosis (CF) ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...

The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis in people 6 years and older who have mutations that are amenable to the therapy ...

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB ... In respiratory, KB407 is being investigated for cystic fibrosis, the most common inherited genetic disorder in the US.

"4DMT reveals positive interim Phase I/II data for cystic fibrosis gene therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

The "Transfection Reagents & Equipment Market by Product, by Method, by Application, by End-User, and By Region" report has ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis ...